Recently diagnosed with HIV? Click here

SKiT (abacavir to tenofovir)

Clinical trial • No longer enrolling • 8 April 2009
This trial is no longer enrolling. This may mean the trial is fully enrolled, or that enrolment in the trial has been halted or suspended. You cannot enrol in this trial.

About this trial

The purpose of this study is to evaluate cardiovascular function in HIV-infected adults before and after switching their HIV treatment from Kivexa to Truvada (or from Abacavir to Tenofovir).
The theory being tested is that markers of cardiovascular function (as measured by applanation tonometry*) will improve in patients switching from ABC-3TC to TDF-FTC.

Background information

*Tonometry is a procedure which measures the pressure inside the eyes. An applanation tonometer is an instrument for determining ocular tension by application of a small flat disk to the cornea.

Official title:Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir) in people with Human Immunodeficiency Virus (HIV).
What is this trial studying?Side effect management – tenofovir, Truvada
Start date:actual start date: 23/09/2008

This may be the proposed or expected start date for trials which have not yet started.

How many participants will this trial enrol?20

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

How long is this trial planned to go for?Participants in this trial will be asked to follow the trial protocol for 24 weeks.
Links to further information:
Tags:heart disease

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • Currently taking HIV treatments
  • Viral load below 50 copies/ml
  • Has been on stable antiretroviral therapy including abacavir (ABC) or ABC-3TC for at least six months.

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Disclaimer

While NAPWHA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 8 April 2009 — more than four years ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWHA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWHA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWHA Clinical Trials database.

more